Acurx Pharmaceuticals, Inc. (ACXP) Income Statement
ACXP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsACXP revenue and net income
ACXP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ACXP quarterly EPS vs estimates
Acurx Pharmaceuticals beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.45).
ACXP income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.83B | $5.4M | $6.0M | $4.8M | $2.0M | $2.2M | $3.5M |
| Sales, general & admin | $6.26B | $8.7M | $8.5M | $7.3M | $10.8M | $2.4M | $2.4M |
| Total operating expenses | $8.1M | $14.1M | $14.6M | $12.1M | $12.8M | $4.6M | $5.9M |
| Operating income | −$8.1M | −$14.1M | −$14.6M | −$12.1M | −$12.9M | −$4.6M | −$5.9M |
| Interest income | $125,445 | $20,124 | — | — | — | — | — |
| Interest expense | — | — | — | $1,224 | $66,503 | $0 | $0 |
| Income before taxes | −$8.0M | −$14.1M | −$14.6M | −$12.1M | −$12.7M | −$4.6M | −$5.9M |
| Income taxes | — | −$14.09B | −$14,577 | −$1,224 | −$66,503 | −$4,598 | −$5,934 |
| Net income | −$8.0M | −$14.1M | −$14.6M | −$12.1M | −$12.7M | −$4.6M | −$5.9M |
| EBITDA | −$8.0M | $20,124 | −$14.6M | −$12.1M | −$12.8M | −$4.6M | −$5.9M |
| EPS (diluted) | −$5.63 | −$14.36 | −$11.02 | −$22.40 | −$1.48 | −$0.47 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.1M | $341,468 | $1.83B | $429,691 | $524,210 | $598,798 | $825,059 | $1.2M | $1.8M | $1.6M | $1.9M | $1.3M |
| Sales, general & admin | $1.2M | $1.37B | $6.25B | $1.6M | $1.7M | $1.6M | $2.0M | $1.6M | $2.3M | $2.8M | $3.2M | $1.8M |
| Total operating expenses | $2.3M | $1.7M | $1.6M | $2.0M | $2.3M | $2.1M | $2.8M | $2.8M | $4.1M | $4.4M | $5.1M | $3.1M |
| Operating income | −$2.3M | −$1.7M | −$1.6M | −$2.0M | −$2.3M | −$2.1M | −$2.8M | −$2.8M | −$4.1M | −$4.4M | −$5.1M | −$3.1M |
| Interest income | $53,055 | $35,008 | $38,840 | $35,911 | $23,404 | $27,291 | — | $5,001 | $782 | — | — | — |
| Income before taxes | −$2.3M | −$1.7M | −$1.6M | −$2.0M | −$2.2M | −$2.1M | −$2.8M | −$2.8M | −$4.1M | −$4.4M | −$5.1M | −$3.1M |
| Income taxes | — | — | — | — | — | — | $4.4M | — | −$4.1M | −$4.4M | −$5,114 | −$3,115 |
| Net income | −$2.3M | −$1.7M | −$1.6M | −$2.0M | −$2.2M | −$2.1M | −$2.8M | −$2.8M | −$4.1M | −$4.4M | −$5.1M | −$3.1M |
| EBITDA | −$2.3M | −$1.7M | −$1.6M | −$2.0M | −$2.2M | −$2.1M | −$2.8M | −$2.8M | −$4.1M | −$4.4M | −$5.1M | −$3.1M |
| EPS (diluted) | −$0.53 | −$0.62 | −$0.31 | −$1.23 | −$1.89 | −$2.20 | −$0.16 | −$3.40 | −$5.20 | −$5.60 | −$0.37 | −$4.80 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ACXP's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ACXP financial results
Acurx Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $8.0 million. Diluted earnings per share came to −$5.63.
See the ACXP stock overview for the latest quote and news, or the ACXP chart for price history and technical indicators.
ACXP income statement FAQ
Does Acurx Pharmaceuticals have revenue?
Acurx Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Acurx Pharmaceuticals profitable?
No. Acurx Pharmaceuticals reported a net loss of $8.0 million in fiscal 2025.
How much does Acurx Pharmaceuticals spend on research and development?
Acurx Pharmaceuticals spent $1.8 billion on research and development in fiscal 2025.
What are Acurx Pharmaceuticals's earnings per share?
Acurx Pharmaceuticals earned $-5.63 per diluted share in fiscal 2025, compared with $-14.36 a year earlier.
When will Acurx Pharmaceuticals report its next earnings?
Acurx Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Acurx Pharmaceuticals's fiscal year end?
Acurx Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.